

CERTIFICATE

Survey of 17 May 2017

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 13 - NM Heparin (281):

Validity 12 months:

anti-Xa-Activ.(unfr. Heparine)

Haemostasis 22 - Dabigatran (502):

Validity 12 months:

Dabigatran

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

Haemostasis 25 - Apixaban (504):

Validity 12 months:

Apixaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD


U Nemocnice 2

12808 Praha 2

Düsseldorf, 13 July 2017



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)